Suppr超能文献

在全国健康和营养调查中,糖尿病、糖尿病前期和非糖尿病女性中胰岛素增敏剂的使用模式。

Patterns of use of insulin-sensitizing agents among diabetic, borderline diabetic and non-diabetic women in the National Health and Nutrition Examination Surveys.

机构信息

Graduate Program in Public Health, Eastern Virginia Medical School, Norfolk, VA 23501-1980, USA.

出版信息

Gynecol Endocrinol. 2013 Apr;29(4):350-6. doi: 10.3109/09513590.2012.752457. Epub 2013 Jan 17.

Abstract

The purpose of this cross-sectional study based on the 2001-2006 National Health and Nutrition Examination Survey is to examine demographic, socioeconomic, lifestyle and reproductive characteristics that may distinguish users and non-users of insulin sensitizing agents among the US diabetic, borderline diabetic and non-diabetic women. Use of insulin-sensitizing agents was evaluated among 19,579 (3882 diabetic, 387 borderline diabetic and 15,310 non-diabetic) women. Overall, 2% of women in the study sample were users of insulin-sensitizers, including metformin, rosiglitazone and pioglitazone. Multivariate logistic regression models were constructed for predictors of insulin-sensitizer use according to diabetic status. In the overall sample, being younger or diabetic were the only factors associated with an increased odds of using insulin-sensitizing agents, after adjustment of confounders. Among diabetics, use of insulin-sensitizing agents was inversely related to age, but not other factors in the multivariable model. Among borderline and non-diabetics, body mass index (BMI) was the only predictor that remained significantly associated with the use of insulin-sensitizing agents after controlling for confounders. In conclusion, the main predictors of insulin-sensitizer use are young age and diabetic status in all women, young age in diabetic women and high BMI in borderline and non-diabetic women.

摘要

本横断面研究基于 2001-2006 年全国健康和营养调查,旨在研究美国糖尿病、边缘型糖尿病和非糖尿病女性中可能区分胰岛素增敏剂使用者和非使用者的人口统计学、社会经济、生活方式和生殖特征。在 19579 名(3882 名糖尿病患者、387 名边缘型糖尿病患者和 15310 名非糖尿病患者)女性中评估了胰岛素增敏剂的使用情况。总的来说,研究样本中有 2%的女性使用胰岛素增敏剂,包括二甲双胍、罗格列酮和吡格列酮。根据糖尿病状况,建立了多变量逻辑回归模型,以预测胰岛素增敏剂的使用。在总体样本中,在调整了混杂因素后,年轻或糖尿病是与使用胰岛素增敏剂的几率增加相关的唯一因素。在糖尿病患者中,使用胰岛素增敏剂与年龄呈反比,但在多变量模型中与其他因素无关。在边缘型和非糖尿病患者中,体重指数(BMI)是在控制混杂因素后与使用胰岛素增敏剂仍显著相关的唯一预测因素。总之,所有女性中胰岛素增敏剂使用的主要预测因素是年龄较小和糖尿病状态,糖尿病女性的主要预测因素是年龄较小,边缘型和非糖尿病女性的主要预测因素是 BMI 较高。

相似文献

5
Metformin and pioglitazone: Effectively treating insulin resistance.
Curr Med Res Opin. 2006;22 Suppl 2:S27-37. doi: 10.1185/030079906X112732.
6
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Clin Ther. 2003;25 Suppl B:B47-63. doi: 10.1016/s0149-2918(03)80242-4.
8
[Insulin sensitizing drugs].
Vnitr Lek. 2009 Apr;55(4):425-8.
10

本文引用的文献

2
Limitations of metformin use in patients with kidney disease: are they warranted?
Diabetes Obes Metab. 2010 Dec;12(12):1079-83. doi: 10.1111/j.1463-1326.2010.01295.x.
5
Pioglitazone: beyond glucose control.
Expert Rev Cardiovasc Ther. 2010 Aug;8(8):1057-67. doi: 10.1586/erc.10.98.
6
Pioglitazone: side effect and safety profile.
Expert Opin Drug Saf. 2010 Mar;9(2):347-54. doi: 10.1517/14740331003623218.
7
Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004.
Cancer Causes Control. 2010 May;21(5):671-8. doi: 10.1007/s10552-009-9494-9. Epub 2010 Jan 14.
8
Troglitazone.
Handb Exp Pharmacol. 2010(196):419-35. doi: 10.1007/978-3-642-00663-0_14.
9
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Adv Ther. 2009 Oct;26(10):893-907. doi: 10.1007/s12325-009-0072-z. Epub 2009 Nov 16.
10
Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen.
Urology. 2010 Nov;76(5):1042-6. doi: 10.1016/j.urology.2009.05.100. Epub 2009 Sep 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验